{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Partial Response"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Stable Disease"},{"measurements":[{"groupId":"OG000","value":"8"}],"title":"Progressive Disease"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Not Evaluable"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"ORR was evaluated based upon the best overall response (BOR) for individual study subjects. BOR was determined by the highest post-baseline qualitative response value for each assessed subject as measured by modified response evaluation criteria in solid tumors (modified RECIST) for MPM (Byrne and Nowak, 2004) and given the following hierarchy of overall response results: complete response (CR) \\> partial response (PR) \\> stable disease (SD) \\> progressive disease (PD) \\> not evaluable (NE). The protocol-specified ORR was defined as the percentage of evaluable subjects with a BOR of CR or PR; however, this percentage was not calculated per the final study Statistical Analysis Plan (SAP). Therefore, the number of evaluable subjects with BOR RECIST v1.1 values of CR, PR, SD, PD, and NE are provided for this outcome measure.","groups":[{"description":"CRS-207 and pembrolizumab were administered in 3-week cycles. For Cycle 1, pembrolizumab (200 mg) was administered by IV infusion over 30 minutes on Day 1 and CRS-207 (starting dose 1 × 10e9 CFU) was administered by IV infusion over 1 hour on Day 2. If tolerated, pembrolizumab and CRS-207 were administered on the same day (Day 1) for subsequent cycles. After 4 cycles, pembrolizumab continued to be administered on Day 1 at each treatment cycle (every 3 weeks); and CRS-207 was administered once every 6 weeks (every other cycle).","id":"OG000","title":"Experimental"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Analysis based on subjects who received ≥1 dose of study treatment and had ≥1 evaluable post-baseline modified RECIST for MPM tumor response assessment or were discontinued due to toxicity (the Evaluable Analysis Set \\[EAS\\]). 1 subject did not have post-baseline tumor response assessments and could not be evaluated for this outcome measure.","reportingStatus":"POSTED","timeFrame":"BOR was assessed from the first dose of study treatment until documented disease progression, initiation of new cancer treatment, death, or study termination, whichever is earlier, assessed up to 15 weeks.","title":"Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Participants"}